TILT Biotherapeutics Ltd.

13 articles with TILT Biotherapeutics Ltd.

• TILT Biotherapeutics Announces Data at ESMO on Its Oncolytic Immunotherapy Platform

  9/17/2021

  TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that the company presented yesterday clinical study results at the annual congress of the European Society of Molecular Oncology.

• TILT Biotherapeutics Reports Publication on its Oncolytic Immunotherapy Platform in Pancreatic Cancer

  8/27/2021

  TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that new preclinical data relating to the use of its oncolytic immunotherapy platform for expressing a human IL-2 variant protein has been published in Frontiers in Immunology.

• 

  Clinical Catch-Up: June 14-18

  6/21/2021

  It was another busy week of clinical trial announcements. Here’s a look.

• TILT Biotherapeutics Submits IND for Phase I Trial of Immunotherapeutic TILT-123 in Ovarian Cancer

  6/14/2021

  TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has submitted an IND for its Phase I trial of immunotherapeutic TILT-123 in ovarian cancer.

•  TILT Biotherapeutics, Docrates Cancer Center and Helsinki University Hospital Open Cancer Immunotherapy Clinical Trial

  5/5/2021

  TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces that it has dosed its first patients and progressed to the second dose level in a monotherapy phase 1 clinical trial of TILT-123, a dual cytokine armed oncolytic adenovirus.

• TILT Biotherapeutics and MSD to Collaborate on Clinical Trial of Adenoviral Cancer Immunotherapeutic TILT-123 in Combination with KEYTRUDA® (pembrolizumab) for Ovarian Cancer

  4/14/2021

  TILT Biotherapeutics announced a clinical trial collaboration agreement with MSD, a premier research-intensive biopharmaceutical company, to evaluate TILT’s adenoviral cancer immunotherapy TILT-123, a dual cytokine armed oncolytic adenovirus, in combination with KEYTRUDA®, MSD’s anti-PD-1 therapy, in a Phase I dose escalation trial in platinum resistant or refractory ovarian cancer.

• TILT Biotherapeutics Announces Two Patients Pass Primary Safety Endpoint in European Cancer Immunotherapy Trial

  9/28/2020

  TILT Biotherapeutics, a clinical-stage biotechnology company developing cancer immunotherapeutics, announces it has dosed two patients in a phase 1 clinical trial of its dual cytokine armed oncolytic adenovirus, TILT-123, in Denmark’s Herlev hospital in Copenhagen.

• TILT Biotherapeutics Secures Over EUR 6 million to Advance Cancer Immunotherapies Into Clinic

  6/16/2020

  EUR 18m raised to date, with investors including Lifeline Ventures, Finnish private investors, the European Innovation Council and Business Finland

• TILT Biotherapeutics Signs a Licensing Deal with Biotheus, Inc for Cancer Therapy with Oncolytic Virus TILT-123

  1/27/2020

  TILT Biotherapeutics (“TILT”), a privately held biopharmaceutical company based in Helsinki, Finland, today announces that they have signed a license agreement with Biotheus Inc. (“Biotheus”), a privately held Chinese company based in Zhuhai, Guangdong, China.

• TILT Holdings Announces CMW Media as Strategic Communications Firm

  7/31/2019

  Engagement highlights TILT’s renewed focus on corporate communication

• TILT Biotherapeutics Initiates Collaboration With Merck KGaA, Darmstadt, Germany and Pfizer Investigating the Combination of Oncolytic Virus, TILT-123, And Anti-PDL1 Antibody, Avelumab

  6/25/2019

  Agreement to evaluate its armed oncolytic virus, TILT-123, with avelumab in patients with solid tumors refractory to routine modalities.

• TILT Biotherapeutics Wins a Grant from European Commission for a Phase 1 Clinical Trial

  6/4/2018

  TILT Biotherapeutics Ltd has won a grant for a 2.5 M€ (~$ 2.9M) project, entitled UNLEASHAD, from the European Commission EIC SME Instrument.

• TILT Biotherapeutics Secures $10.6 Million for Viral Cancer T-Cell Immunotherapy

  12/14/2016